Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30763153 | 1.00 | THRB (0.87) | THRBTHRA | |
| SCHEMBL19617451 | 0.93 | THRB (1.00) | THRBTHRA | |
| Sobetirome SCHEMBL29467327 | 0.92 | THRB (1.00) | THRBTHRA | |
| Sobetirome SCHEMBL282119 | 0.92 | THRB (1.00) | THRBTHRA | |
| SCHEMBL22106256 | 0.91 | THRB (0.91) | THRBTHRA | |
| SCHEMBL30762937 | 0.91 | THRB (0.91) | THRBTHRA | |
| SCHEMBL22095710 | 0.90 | THRB (0.91) | THRBTHRA | |
| SCHEMBL22100242 | 0.89 | THRB (0.70) | THRBTHRA | |
| SCHEMBL22100248 | 0.89 | THRB (0.70) | THRBTHRA | |
| SCHEMBL30763009 | 0.89 | THRB (0.70) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827596-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827596-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827596-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| CN-113423684-A | Novel thyromimetic agents | 速通医疗公司 | 2021-09-21 | — | — | CN | disclosed |
| US-20200361849-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200361849-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2020118564-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123861-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361849-A1 | NOVEL THYROMIMETICS | TPO, THOP1, TSHR | THRB 12/4885THRA 9/4885 |
| US-11827596-B2 | Thyromimetics | TPO, TSHR, TTR | THRB 9/4885THRA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.